This review concluded that survival rates were comparable between surgical resection and percutaneous radiofrequency ablation for early stage hepatocellular carcinoma patients with good liver function, but complications were more frequent and hospital stay longer after surgical resection; other evidence was less clear. Given the limitations of the data and review reporting, the authors' findings should be interpreted with caution.
Searching
MEDLINE and EMBASE were searched for studies published in peer-reviewed journals in English, French or Chinese from January 2006 to January 2009; other languages were considered if the abstracts, tables and figures were understandable. Search terms were reported. Studies published before January 2006 were identified from a health technology assessment published by the Australian Safety and Efficacy Register of New Interventional Procedures (ASERNIP-S). Further studies were sought through screening the reference lists of retrieved studies.
Study selection
Randomised controlled trials (RCTs) and non-randomised comparative cohort studies that compared the clinical effectiveness and cost of percutaneous radiofrequency ablation versus surgical resection for the management of patients with early stage hepatocellular carcinoma (Child-Pugh score of A or B and tumour size over 5cm) were eligible for inclusion in the review. Eligible studies had to have a mean or median follow-up time of at least one year and report survival rates. Cohort studies had to have an average sample size per treatment group of over 50 participants.
Patient inclusion criteria varied between the included studies. Half of the studies included only patients with Child-Pugh Class A hepatocellular carcinoma; the average tumour size in these studies was 3cm or less. One third of the studies included both Child-Pugh Class A and B patients with a median tumour size of over 3cm. In all but one of the studies, the number of tumours per patient was one. The mean age of included participants ranged from 49 to 58 years; the median age ranged from 66 to 69 years (where reported). The proportion of men ranged from 70 to 83%. Overall and disease-free survival, local and distant recurrence rates, and complication rates were reported. The included studies were conducted in Italy, China, Japan, Korea, and South Korea.
It was unclear how many reviewers assessed the studies for inclusion.
Assessment of study quality
The authors did not state that they assessed study quality.
Data extraction
One reviewer extracted the study data and a second reviewer cross-checked for accuracy. Where available, percentage rates were extracted for overall survival and disease-free survival rates (at one, three and five years), local and distant recurrence rates, and major complications. Where cumulative survival rates were not available, they were estimated from Kaplan-Meier curves. Study authors were contacted to provide further data and clarification when necessary.
Methods of synthesis
Studies were subgrouped according to the Child-Pugh classification of the patients. The authors report using separate meta-analyses to calculate pooled one-year, three-year and five-year survival rates of each treatment strategy within two subgroups of studies; those with Child-Pugh A patients alone and those with a mix of Child-Pugh A and B patients.
